Aura Biosciences (AURA) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.47
- EPS estimate
- −$0.48
- EPS surprise
- +1.67%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 13, 2025
The newest results in the table are for Q2 2025, which Aura Biosciences reported on August 13, 2025. The company posted a loss of $0.47 per share, slightly narrower than the $0.48 loss expected, a 1.67% beat. The table gives no revenue figures or estimates for Aura. Compared with Q2 2024, the loss widened from $0.41 per share.
All 16 quarters in the table, from Q3 2021 to Q2 2025, were losses, mostly between $0.40 and $0.56 per share. The narrowest was $0.39 in Q3 2021 and the widest $0.56 in Q4 2021. Annual losses were $1.96 per share in 2022, $1.93 in 2023 and $1.75 in 2024. The first half of 2025 added up to a loss of $1.02 per share, wider than the $0.81 loss in the first half of 2024. Results compared with estimates were mixed: Aura beat the EPS estimate in 9 of the 16 quarters and missed in 7.
Aura reported its third-quarter results between November 9 and November 24 in 2021 through 2024, but the table has no Q3 2025 row or later quarters. The next row to appear will be Q3 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 13, 2025 | −$0.48 | −$0.47 | +1.67% | $0.00 | SEC |
| Q1 2025 | May 15, 2025 | −$0.49 | −$0.55 | −12.02% | $0.00 | SEC |
| Q4 2024 | Mar 24, 2025 | −$0.44 | −$0.52 | −17.20% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.44 | −$0.42 | +4.78% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.45 | −$0.41 | +8.91% | $0.00 | SEC |
| Q1 2024 | May 9, 2024 | −$0.49 | −$0.40 | +17.70% | $0.00 | SEC |
| Q4 2023 | Mar 27, 2024 | −$0.42 | −$0.51 | −21.11% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.52 | −$0.48 | +7.83% | $0.00 | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.49 | −$0.48 | +2.04% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$0.54 | −$0.46 | +14.81% | $0.00 | SEC |
| Q4 2022 | Mar 15, 2023 | −$0.51 | −$0.52 | −2.77% | $0.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$0.53 | −$0.54 | −1.89% | $0.00 | SEC |
| Q2 2022 | Aug 11, 2022 | −$0.46 | −$0.46 | −0.13% | $0.00 | SEC |
| Q1 2022 | May 12, 2022 | −$0.58 | −$0.44 | +23.70% | $0.00 | SEC |
| Q4 2021 | Mar 23, 2022 | −$0.39 | −$0.56 | −42.38% | $0.00 | SEC |
| Q3 2021 | Nov 24, 2021 | −$0.76 | −$0.39 | +48.91% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Aura Biosciences (AURA) last report earnings?
Aura Biosciences last reported on Aug 13, 2025, covering fiscal Q2 2025.
Did AURA beat earnings estimates?
Yes. Aura Biosciences reported EPS of −$0.47 for Q2 2025 against a −$0.48 estimate — a 1.67% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.